Abstract 365P
Background
Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in Malaysia and the incidence rate is high in the state of Sabah. Patients in Sabah are known to have limitations to access the healthcare services in the state. The purpose of this study is to examine the survival results, failure patterns, and compliance rate of patients with nasopharyngeal cancer who received radical radiotherapy with or without chemotherapy in Sabah.
Methods
A retrospective analysis was performed on patients diagnosed with stage I-IVA (AJCC staging 8th edition) NPC and treated with radiotherapy between the years of 2017-2019 in Sabah Women and Children's Hospital. The Kaplan-Meier method was used for survival analysis and differences in survival according to AJCC stage was compared using the log-rank test.
Results
A total of 140 patients were treated during this period. Most of them presented late at diagnosis, stage III (39%) and stage IVA (40%). Majority of them were treated with IMRT technique (85%). The compliance rate to radiotherapy was 96%. The 3-year overall survival (OS), disease-free-survival (DFS), local-failure-free survival (LFFS), regional-failure-free survival (RFFS), distant-failure-free survival (DFFS), of NPC patients in this study are 70%, 61%, 83%, 84%, and 67% respectively. The LFFS was significantly different between T stages (P value = 0.003) and T4 stage had the lowest rate of 3-year LFFS (65%). The RFFS was significantly different between N stages (P value = 0.013) and the 3-year RFFS probability for N3 stage was markedly lower than the rest (63%). The DFFS was significantly different between N stages (P-value < 0.001) and the 3-year DFFS probability decreased as N stage increased.
Conclusions
The 3-year OS and 3-year DFS rates in our study are comparable to those in peninsular Malaysia. The LFFS for T1-T3 stages is high. However, LFFS is low in T4 disease and DFFS is significantly low in N3 disease. Hence prospective studies are needed to determine if this group of patients may benefit from an intensified systemic treatment. Despite facing many challenges to access healthcare in Sabah, NPC patients in the state have a remarkably high compliance rate to radiotherapy treatment.
Clinical trial identification
NMRR ID-23-00055-E3N; RSCH ID-22-02599-GSk.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract